Relationship Between Cerebrospinal Fluid Alzheimer's Disease Biomarker Values Measured via Lumipulse Assays and Conventional ELISA: Single-Center Experience and Systematic Review

J Alzheimers Dis. 2024;99(3):1077-1092. doi: 10.3233/JAD-240185.

Abstract

Background: Although Lumipulse assays and conventional ELISA are strongly correlated, the precise relationship between their measured values remains undetermined.

Objective: To determine the relationship between Lumipulse and ELISA measurement values.

Methods: Patients who underwent cerebrospinal fluid (CSF) Alzheimer's disease (AD) biomarker measurements and consented to biobanking between December 2021 and June 2023 were included. The relationship between values measured via Lumipulse assays and conventional ELISA were evaluated by Passing-Bablok analyses for amyloid-β 1-42 (Aβ42), total tau (t-tau), and phospho-tau 181 (p-tau 181). Studies using both assays were systematically searched for in PubMed and summarized after quality assessment.

Results: Regression line slopes and intercepts were 1.41 (1.23 to 1.60) and -77.8 (-198.4 to 44.5) for Aβ42, 0.94 (0.88 to 1.01) and 98.2 (76.9 to 114.4) for t-tau, and 1.60 (1.43 to 1.75) and -21.1 (-26.9 to -15.6) for p-tau181. Spearman's correlation coefficients were 0.90, 0.95, and 0.95 for Aβ42, t-tau, and p-tau181, respectively. We identified 13 other studies that included 2,117 patients in total. Aβ42 slope varied among studies, suggesting inter-lab difference of ELISA. The slope and intercept of t-tau were approximately 1 and 0, respectively, suggesting small proportional and systematic differences. Conversely, the p-tau181 slope was significantly higher than 1, distributed between 1.5-2 in most studies, with intercepts significantly lower than 0, suggesting proportional and systematic differences.

Conclusions: We characterized different relationship between measurement values for each biomarker, which may be useful for understanding the differences in CSF biomarker measurement values on different platforms and for future global harmonization.

Keywords: Alzheimer’s disease; amyloid-β; biomarkers; cerebrospinal fluid; chemiluminescent enzyme immunoassay (CLEIA); enzyme-linked immunosorbent assay (ELISA); fully-automated; standardization; systematic review; tau proteins.

Publication types

  • Systematic Review

MeSH terms

  • Alzheimer Disease* / cerebrospinal fluid
  • Alzheimer Disease* / diagnosis
  • Amyloid beta-Peptides* / cerebrospinal fluid
  • Biomarkers* / cerebrospinal fluid
  • Enzyme-Linked Immunosorbent Assay* / methods
  • Humans
  • Peptide Fragments* / cerebrospinal fluid
  • tau Proteins* / cerebrospinal fluid

Substances

  • Biomarkers
  • Amyloid beta-Peptides
  • tau Proteins
  • Peptide Fragments
  • amyloid beta-protein (1-42)